Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials

A. Belkouz, J. W. Wilmink, N. Haj Mohammad, J. Hagendoorn, J. de Vos-Geelen, C. H. C. Dejong, M. Y. V. Homs, B. Groot Koerkamp, T. M. van Gulik, M. G. H. van Oijen, C. J. A. Punt, H. Klumpen*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Article number102975
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume151
DOIs
Publication statusPublished - Jul 2020

Keywords

  • Cholangiocarcinoma
  • Biliary tract cancer
  • Adjuvant therapy
  • Neoadjuvant therapy
  • Chemotherapy
  • Chemoradiotherapy
  • PERIHILAR CHOLANGIOCARCINOMA
  • GEMCITABINE CHEMOTHERAPY
  • GALLBLADDER CARCINOMA
  • PROGNOSTIC-FACTORS
  • PLUS GEMCITABINE
  • RESECTION
  • CISPLATIN
  • SURVIVAL
  • S-1
  • OXALIPLATIN

Cite this

Belkouz, A., Wilmink, J. W., Mohammad, N. H., Hagendoorn, J., de Vos-Geelen, J., Dejong, C. H. C., Homs, M. Y. V., Koerkamp, B. G., van Gulik, T. M., van Oijen, M. G. H., Punt, C. J. A., & Klumpen, H. (2020). Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials. Critical Reviews in Oncology/Hematology, 151, [102975]. https://doi.org/10.1016/j.critrevonc.2020.102975